Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 229

1.

The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2.

Abdel-Fatah TMA, Rees RC, Pockley AG, Moseley P, Ball GR, Chan SYT, Ellis IO, Miles AK.

Oncotarget. 2017 Nov 18;8(68):112245-112257. doi: 10.18632/oncotarget.22496. eCollection 2017 Dec 22.

2.

A novel spontaneous model of epithelial-mesenchymal transition (EMT) using a primary prostate cancer derived cell line demonstrating distinct stem-like characteristics.

Harner-Foreman N, Vadakekolathu J, Laversin SA, Mathieu MG, Reeder S, Pockley AG, Rees RC, Boocock DJ.

Sci Rep. 2017 Jan 17;7:40633. doi: 10.1038/srep40633.

3.

SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.

Abdel-Fatah TMA, Agarwal D, Liu DX, Russell R, Rueda OM, Liu K, Xu B, Moseley PM, Green AR, Pockley AG, Rees RC, Caldas C, Ellis IO, Ball GR, Chan SYT.

Lancet Oncol. 2016 Jul;17(7):1004-1018. doi: 10.1016/S1470-2045(16)00174-1. Epub 2016 Jun 14.

PMID:
27312051
4.

Prediction of Pathological Stage in Patients with Prostate Cancer: A Neuro-Fuzzy Model.

Cosma G, Acampora G, Brown D, Rees RC, Khan M, Pockley AG.

PLoS One. 2016 Jun 3;11(6):e0155856. doi: 10.1371/journal.pone.0155856. eCollection 2016.

5.

Cytoplasmic PML promotes TGF-β-associated epithelial-mesenchymal transition and invasion in prostate cancer.

Buczek ME, Miles AK, Green W, Johnson C, Boocock DJ, Pockley AG, Rees RC, Hulman G, van Schalkwyk G, Parkinson R, Hulman J, Powe DG, Regad T.

Oncogene. 2016 Jun 30;35(26):3465-75. doi: 10.1038/onc.2015.409. Epub 2015 Nov 9.

6.

HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.

Abdel-Fatah TM, McArdle SE, Agarwal D, Moseley PM, Green AR, Ball GR, Pockley AG, Ellis IO, Rees RC, Chan SY.

Clin Cancer Res. 2016 Feb 15;22(4):905-14. doi: 10.1158/1078-0432.CCR-15-0610. Epub 2015 Aug 3.

7.

Data Mining of Gene Arrays for Biomarkers of Survival in Ovarian Cancer.

Coveney C, Boocock DJ, Rees RC, Deen S, Ball GR.

Microarrays (Basel). 2015 Jul 17;4(3):324-38. doi: 10.3390/microarrays4030324.

8.

Controlling the dynamics of cell transition in heterogeneous cultures using surface chemistry.

Hickman GJ, Rees RC, Boocock DJ, Pockley AG, Perry CC.

Adv Healthc Mater. 2015 Mar 11;4(4):593-601. doi: 10.1002/adhm.201400525. Epub 2014 Nov 13.

PMID:
25393206
9.

Prostate cancer: Important steps and considerations in the design of therapeutic vaccines.

McArdle SE, Pockley AG, Gibson GR, Rees RC.

Oncoimmunology. 2014 Feb 14;3:e28049. eCollection 2014.

10.

HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer.

Abdel-Fatah TM, McArdle SE, Johnson C, Moseley PM, Ball GR, Pockley AG, Ellis IO, Rees RC, Chan SY.

Br J Cancer. 2014 May 13;110(10):2450-61. doi: 10.1038/bjc.2014.168. Epub 2014 Apr 22.

11.

The helicase HAGE prevents interferon-α-induced PML expression in ABCB5+ malignant melanoma-initiating cells by promoting the expression of SOCS1.

Mathieu MG, Miles AK, Ahmad M, Buczek ME, Pockley AG, Rees RC, Regad T.

Cell Death Dis. 2014 Feb 13;5:e1061. doi: 10.1038/cddis.2014.29.

12.

Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.

Saif JM, Vadakekolathu J, Rane SS, McDonald D, Ahmad M, Mathieu M, Pockley AG, Durrant L, Metheringham R, Rees RC, McArdle SE.

Eur J Immunol. 2014 Apr;44(4):994-1004. doi: 10.1002/eji.201343863. Epub 2014 Mar 7.

13.

Virulence loss and amastigote transformation failure determine host cell responses to Leishmania mexicana.

Ali KS, Rees RC, Terrell-Nield C, Ali SA.

Parasite Immunol. 2013 Dec;35(12):441-56. doi: 10.1111/pim.12056.

14.

Identification of novel breast cancer-associated transcripts by UniGene database mining and gene expression analysis in normal and malignant cells.

Laversin SA, Phatak VM, Powe DG, Li G, Miles AK, Hughes DC, Ball GR, Ellis IO, Gritzapis AD, Missitzis I, McArdle SE, Rees RC.

Genes Chromosomes Cancer. 2013 Mar;52(3):316-29. doi: 10.1002/gcc.22031. Epub 2012 Dec 8.

PMID:
23225347
15.

The helicase HAGE expressed by malignant melanoma-initiating cells is required for tumor cell proliferation in vivo.

Linley AJ, Mathieu MG, Miles AK, Rees RC, McArdle SE, Regad T.

J Biol Chem. 2012 Apr 20;287(17):13633-43. doi: 10.1074/jbc.M111.308973. Epub 2012 Mar 5.

16.

Expression of the tumour antigen T21 is up-regulated in prostate cancer and is associated with tumour stage.

Miles AK, Rogers A, McCulloch T, Hodi Z, McArdle S, Bishop M, Rees RC.

BJU Int. 2012 Mar;109(5):796-805. doi: 10.1111/j.1464-410X.2011.10407.x. Epub 2011 Aug 18.

17.

Immunotherapy of prostate cancer: should we be targeting stem cells and EMT?

Dunning NL, Laversin SA, Miles AK, Rees RC.

Cancer Immunol Immunother. 2011 Aug;60(8):1181-93. doi: 10.1007/s00262-011-1065-8. Epub 2011 Jun 19. Review.

PMID:
21688178
18.

Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial.

McCarville MB, Luo Z, Huang X, Rees RC, Rogers ZR, Miller ST, Thompson B, Kalpatthi R, Wang WC; BABY HUG Investigators.

AJR Am J Roentgenol. 2011 Jun;196(6):1399-404. doi: 10.2214/AJR.10.4664.

19.

Tumour-associated antigens: considerations for their use in tumour immunotherapy.

Linley AJ, Ahmad M, Rees RC.

Int J Hematol. 2011 Mar;93(3):263-273. doi: 10.1007/s12185-011-0783-1. Epub 2011 Mar 1. Review.

PMID:
21360066
20.

Cancer/testis antigens for therapeutic use.

Mathieu MG, Miles AK, Li G, McArdle SE, Rees RC.

J BUON. 2009 Sep;14 Suppl 1:S97-102. Review.

21.

HAGE, a cancer/testis antigen expressed at the protein level in a variety of cancers.

Mathieu MG, Linley AJ, Reeder SP, Badoual C, Tartour E, Rees RC, McArdle SE.

Cancer Immun. 2010 Jan 11;10:2.

22.

Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial.

Ware RE, Rees RC, Sarnaik SA, Iyer RV, Alvarez OA, Casella JF, Shulkin BL, Shalaby-Rana E, Strife CF, Miller JH, Lane PA, Wang WC, Miller ST; BABY HUG Investigators.

J Pediatr. 2010 Jan;156(1):66-70.e1. doi: 10.1016/j.jpeds.2009.06.060.

23.

Adherence to study medication and visits: data from the BABY HUG trial.

Thornburg CD, Rogers ZR, Jeng MR, Rana SR, Iyer RV, Faughnan L, Hassen L, Marshall J, McDonald RP, Wang WC, Huang X, Rees RC; BABY HUG Investigators.

Pediatr Blood Cancer. 2010 Feb;54(2):260-4. doi: 10.1002/pbc.22324.

24.

Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial.

Pavlakis SG, Rees RC, Huang X, Brown RC, Casella JF, Iyer RV, Kalpatthi R, Luden J, Miller ST, Rogers ZR, Thornburg CD, Wang WC, Adams RJ; BABY HUG Investigators.

Pediatr Blood Cancer. 2010 Feb;54(2):256-9. doi: 10.1002/pbc.22282.

25.

Tumor immunology: new perspectives.

McArdle SE, Rees RC.

Cancer Res. 2009 Sep 15;69(18):7157-9. doi: 10.1158/0008-5472.CAN-09-0631. Epub 2009 Sep 8.

26.

The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design.

Thompson BW, Miller ST, Rogers ZR, Rees RC, Ware RE, Waclawiw MA, Iyer RV, Casella JF, Luchtman-Jones L, Rana S, Thornburg CD, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik S, Howard TH, Luck L, Wang WC.

Pediatr Blood Cancer. 2010 Feb;54(2):250-5. doi: 10.1002/pbc.22269.

27.

Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG).

Miller ST, Wang WC, Iyer R, Rana S, Lane P, Ware RE, Li D, Rees RC; BABY-HUG Investigators.

Pediatr Blood Cancer. 2010 Feb;54(2):265-8. doi: 10.1002/pbc.22189.

28.

Estimation of peptide concentration by a modified bicinchoninic acid assay.

Kapoor KN, Barry DT, Rees RC, Dodi IA, McArdle SE, Creaser CS, Bonner PL.

Anal Biochem. 2009 Oct 1;393(1):138-40. doi: 10.1016/j.ab.2009.06.016. Epub 2009 Jun 17.

PMID:
19539599
29.

CTL responses to Leishmania mexicana gp63-cDNA vaccine in a murine model.

Ali SA, Rezvan H, McArdle SE, Khodadadi A, Asteal FA, Rees RC.

Parasite Immunol. 2009 Jul;31(7):373-83. doi: 10.1111/j.1365-3024.2009.01111.x.

30.

A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks.

Lancashire LJ, Powe DG, Reis-Filho JS, Rakha E, Lemetre C, Weigelt B, Abdel-Fatah TM, Green AR, Mukta R, Blamey R, Paish EC, Rees RC, Ellis IO, Ball GR.

Breast Cancer Res Treat. 2010 Feb;120(1):83-93. doi: 10.1007/s10549-009-0378-1. Epub 2009 Apr 4.

PMID:
19347577
31.

Artificial exosomes as tools for basic and clinical immunology.

De La Peña H, Madrigal JA, Rusakiewicz S, Bencsik M, Cave GW, Selman A, Rees RC, Travers PJ, Dodi IA.

J Immunol Methods. 2009 May 31;344(2):121-32. doi: 10.1016/j.jim.2009.03.011. Epub 2009 Apr 1.

PMID:
19345222
32.

Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable?

Riley CL, Mathieu MG, Clark RE, McArdle SE, Rees RC.

Cancer Immunol Immunother. 2009 Sep;58(9):1489-99. doi: 10.1007/s00262-009-0675-x. Epub 2009 Mar 4. Review.

PMID:
19259670
33.

Quantitative RT-PCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue.

Walton TJ, Li G, McCulloch TA, Seth R, Powe DG, Bishop MC, Rees RC.

Prostate. 2009 Jun 1;69(8):810-9. doi: 10.1002/pros.20929.

PMID:
19189301
34.

MRI abnormalities of the brain in one-year-old children with sickle cell anemia.

Wang WC, Pavlakis SG, Helton KJ, McKinstry RC, Casella JF, Adams RJ, Rees RC; BABY HUG Investigators.

Pediatr Blood Cancer. 2008 Nov;51(5):643-6. doi: 10.1002/pbc.21612.

PMID:
18478575
35.

Identification of gene transcript signatures predictive for estrogen receptor and lymph node status using a stepwise forward selection artificial neural network modelling approach.

Lancashire LJ, Rees RC, Ball GR.

Artif Intell Med. 2008 Jun;43(2):99-111. doi: 10.1016/j.artmed.2008.03.001. Epub 2008 Apr 16.

PMID:
18420392
36.
37.

Identification of immunogenic MHC class II Tyrosinase-derived peptides using HLA-DR1 and HLA-DR4 transgenic mice.

Horton RB, Laversin SA, Reeder SP, Rees RC, McArdle SE.

Protein Pept Lett. 2007;14(5):455-60.

PMID:
17584170
38.

HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides.

Mathieu MG, Knights AJ, Pawelec G, Riley CL, Wernet D, Lemonnier FA, Straten PT, Mueller L, Rees RC, McArdle SE.

Cancer Immunol Immunother. 2007 Dec;56(12):1885-95. Epub 2007 May 9.

PMID:
17487488
39.

Identification of a novel prostate cancer-associated tumor antigen.

Miles AK, Rogers A, Li G, Seth R, Powe D, McArdle SE, McCulloch TA, Bishop MC, Rees RC.

Prostate. 2007 Feb 15;67(3):274-87.

PMID:
17192878
40.

Layer guided-acoustic plate mode biosensors for monitoring MHC-peptide interactions.

Stanley SM, Dodi IA, Evans CR, Paston SJ, Rees RC, Percival CJ, McHale G, Newton MI.

Analyst. 2006 Aug;131(8):892-4. Epub 2006 Jun 28.

PMID:
17028721
41.

The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines.

Assudani DP, Horton RB, Mathieu MG, McArdle SE, Rees RC.

Cancer Immunol Immunother. 2007 Jan;56(1):70-80. Epub 2006 Mar 23. Review.

PMID:
16555057
42.

The identification of human tumour antigens: Current status and future developments.

Miles AK, Matharoo-Ball B, Li G, Ahmad M, Rees RC.

Cancer Immunol Immunother. 2006 Aug;55(8):996-1003. Epub 2006 Jan 12. Review.

PMID:
16408215
43.

Immunity to tumour antigens.

Li G, Ali SA, McArdle SE, Mian S, Ahmad M, Miles A, Rees RC.

Curr Pharm Des. 2005;11(27):3501-9. Review.

PMID:
16248804
44.

Immunotherapeutic potential of DISC-HSV and OX40L in cancer.

Assudani DP, Ahmad M, Li G, Rees RC, Ali SA.

Cancer Immunol Immunother. 2006 Jan;55(1):104-11. Epub 2005 Oct 27. Review.

PMID:
16001161
45.
46.
47.

Peptide immunisation of HLA-DR-transgenic mice permits the identification of a novel HLA-DRbeta1*0101- and HLA-DRbeta1*0401-restricted epitope from p53.

Rojas JM, McArdle SE, Horton RB, Bell M, Mian S, Li G, Ali SA, Rees RC.

Cancer Immunol Immunother. 2005 Mar;54(3):243-53. Epub 2004 Sep 21.

PMID:
15449037
48.

Anti-tumour therapeutic efficacy of OX40L in murine tumour model.

Ali SA, Ahmad M, Lynam J, McLean CS, Entwisle C, Loudon P, Choolun E, McArdle SE, Li G, Mian S, Rees RC.

Vaccine. 2004 Sep 9;22(27-28):3585-94.

PMID:
15315837
49.

Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.

Ahmad M, Rees RC, Ali SA.

Cancer Immunol Immunother. 2004 Oct;53(10):844-54. Epub 2004 Jun 10. Review.

PMID:
15197495
50.

Identification of an HLA-A*0201 cytotoxic T lymphocyte epitope specific to the endothelial antigen Tie-2.

Ramage JM, Metheringham R, Conn A, Spendlove I, Moss RS, Patton DT, Murray JC, Rees RC, Durrant LG.

Int J Cancer. 2004 Jun 10;110(2):245-50.

Supplemental Content

Support Center